Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MALVERN, Pa., April 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will present on-location at NobleCon18 - Noble Capital Markets' Eighteenth Annual Investor Conference.

Ocugen, Inc. to Present at NobleCon18

American Airlines

Moderna

SNDL Inc.

What's popular isn't always what's profitable from an investing standpoint.

4 Ultra-Popular Stocks to Avoid Like the Plague

Investors were probably concerned the expansion of a licensing deal was pricey.

Why Ocugen Stock Tumbled by Nearly 6% Today

Ocugen Inc (NASDAQ: OCGN) and Bharat Biotech have amended their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to include the commercialization of Covaxin in Mexico.  This gives Ocugen Covaxin commercialization rights for.

Why Ocugen Shares Are Trading Higher Today

•  Ocugen responsible for commercialization of COVAXIN™ in Mexico

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

The company's prospects aren't getting better.

2 Red Flags for Ocugen's Future

OCGN stock has declined by over 90% in the past five years. However, that hasn't stopped State Street from more than doubling its position.

State Street Just Bought Ocugen (OCGN) Stock. Here's Why.

Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.

Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study

Shares of OCGN stock are trading lower after the FDA announced that it had placed a clinical hold on Covaxin. Here's what you should know.

Why Is Ocugen (OCGN) Stock Down Today?

Shares of Ocugen Inc. OCGN, -2.03% sank 6.9% premarket, after the biotechnology company said the U.S. Food and Drug Administration placed a "clinical hold" on the Phase 2/3 study of its COVID-19 vaccine candidate Covaxin. Ocugen said the hold was the result of its decision to temporarily pause dosing participants in the study while it evaluates World Health Organization statements following their inspection of Bharat Biotech International Ltd.

Ocugen stock drops after FDA places clinical hold on study of COVID-19 vaccine candidate Covaxin

MALVERN, Pa., April 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced that the Company was informed by the U.S. Food and Drug Administration (FDA) that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ (BBV152), OCU-002, on clinical hold.  This is a result of the Company's decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited's (BBIL) manufacturing facility. We will work with the FDA to address any questions.

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Novavax

Vaxart

Select analysts foresee these coronavirus stocks rocketing higher by 246% to 355% over the next year.

3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall Street

Add the World Health Organization's suspension of Covaxin to the list of troubles that are weighing down OCGN stock. The post What the WHO Snub Means For Ocugen Stock Investors?

What the WHO Snub Means For Ocugen Stock Investors?

Good recent news about a pipeline drug trumped discouraging developments with a licensed coronavirus vaccine.

Why Ocugen Stock Flopped Then Popped Today

Ardelyx

Tonix Pharmaceuticals Hld

Can these biotech penny stocks continue to make gains? The post Hot Biotech Penny Stocks to Watch During the First Full Week of April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch During the First Full Week of April

The company dosed the first patient in a phase 1/2 study of its gene therapy candidate targeting a rare eye disease.

Why Ocugen Stock Is Jumping Today

Announcement marks first clinical trial in humans of Ocugen's modifier gene therapy platform Announcement marks first clinical trial in humans of Ocugen's modifier gene therapy platform

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen's breakthrough moments. The post It's Time to Get Clinical, Not Cynical, With Ocugen Stock appeared first on InvestorPlace.

It's Time to Get Clinical, Not Cynical, With Ocugen Stock

Plug Power

Rivian Automotive

Select analysts believe these fast-paced stocks can soar over the next 12 months.

3 Growth Stocks With Monster Upside of Up to 331%, According to Wall Street

BioNTech SE

Pfizer

The picture is improving for vaccine stocks. But there's still a lot of uncertainty.

Is It Time to Buy COVID-19 Vaccine Stocks Again?

MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022.

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

MALVERN, Pa., March 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the appointment of Jessica Crespo, CPA, as Chief Accounting Officer and Senior Vice President, Finance. She assumed the role effective March 18, 2022.

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

The company's vaccine candidate recently took one step forward.

1 Green Flag for Ocugen in 2022, and 1 Red Flag

MALVERN, Pa., March 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 331,155 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 90,232 shares of common stock to nine newly hired team members. The stock options and RSUs were granted as of March 16, 2022, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sometimes, improved investor sentiment and a revamped website is enough of a catalyst to take something like OCGN stock on a 10% ride higher. The post Why Is Ocugen (OCGN) Stock Up 10% Today?

News for Ocugen, Inc. Stock (OCGN)